Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.